Menu
Search
|

Menu

Close
X

MabVax Therapeutics Holdings Inc MBVX.OQ (NASDAQ Stock Exchange Capital Market)

2.44 USD
+0.08 (+3.39%)
As of 3:59 PM EST
chart
Previous Close 2.36
Open 2.41
Volume 17,859
3m Avg Volume 20,069
Today’s High 2.45
Today’s Low 2.36
52 Week High 10.71
52 Week Low 1.28
Shares Outstanding (mil) 9.16
Market Capitalization (mil) 21.53
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
1
EPS (USD)
FY17
-2.855
FY16
-3.708
FY15
-50.988
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.76
Price to Sales (TTM)
vs sector
--
8.59
Price to Book (MRQ)
vs sector
17.85
5.23
Price to Cash Flow (TTM)
vs sector
--
26.13
Total Debt to Equity (MRQ)
vs sector
147.54
15.32
LT Debt to Equity (MRQ)
vs sector
79.67
11.95
Return on Investment (TTM)
vs sector
-251.91
13.59
Return on Equity (TTM)
vs sector
-557.65
15.20

EXECUTIVE LEADERSHIP

J. David Hansen
Chairman of the Board, President, Chief Executive Officer, Since 2015
Salary: $404,746.00
Bonus: $141,400.00
Gregory Hanson
Chief Financial Officer, Since 2014
Salary: $299,342.00
Bonus: $62,790.00
Philip Livingston
Chief Science Officer, Director, Since 2014
Salary: --
Bonus: --
Paul Maffuid
Vice President - Pharmaceutical Development and Operations, Since 2014
Salary: $294,519.00
Bonus: $61,950.00
Paul Resnick
Vice President and Chief Business Officer, Since 2016
Salary: $212,000.00
Bonus: $44,094.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

11535 Sorrento Valley Rd Ste 400
SAN DIEGO   CA   92121-1309

Phone: +1858.2599405

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform. The Company is focused on the translation into clinical development of products to address the medical needs in the treatment of cancer. The Company's product pipeline includes Therapeutic (MVT-5873), ImmunoPET Imaging (MVT-2163) and Radioimmunotherapy (MVT-1075). The Company’s antibody MVT-5873, is a fully human IgG1 monoclonal antibody (mAb) that targets sialyl Lewis A (sLea), an epitope on CA19-9, and is in Phase I clinical trials as a therapeutic agent for patients with pancreatic cancer (PDAC) and other CA19-9 positive tumors. MVT-5873 includes Therapeutic (MVT-5873) Monotherapy and Therapeutic (MVT-5873)+Chemo, which is targeting pancreatic cancer and other CA19-9 expressing tumors. CA19-9 is expressed in over 90% of PDAC and in other diseases including small cell lung and GI cancers.

SPONSORED STORIES